As Vice President, Research, Greg Babcock oversees all aspects of research including target selection, disease areas of focus, academic partnerships and discovery of novel biologics. Greg joined Visterra in 2013 and has 20 years of experience researching and developing monoclonal antibodies for a variety of disease indications. Previously, Greg served as the Deputy Director of… READ MORE>>

As Vice President, Pharmaceutical Sciences and Technology, Jean Bender is accountable for leading all CMC activities for Visterra’s product pipeline. Prior to Visterra, Jean led the BioProcess Engineering department at Medimmune LLC where she was responsible for process development engineering, scale-up and transfer of drug substance processes. Previously she held roles of increasing responsibility within… READ MORE>>

As Chief Financial Officer, Todd Curtis oversees all Visterra’s finance functions, including finance, accounting, planning and analysis, and tax functions. Todd is also responsible for enterprise systems and facilities. Todd joined Visterra in 2015 and has more than 15 years of finance and operations leadership experience within the biotechnology and software sectors and an additional… READ MORE>>

As Vice President, Intellectual Property & Contracts, Philippe Edouard leads the development and implementation of Visterra’s patent portfolio strategies and supports a range of life science transactions. Philippe joined Visterra in 2020 and has over 20 years combined legal and R&D experience in the life sciences industry. After starting his research career at biotech pioneer… READ MORE>>

As Chief Administrative Officer, Chris Kiefer is responsible for Visterra’s legal, IP, compliance, HR and program and alliance management teams and activities. Chris joined Visterra in 2017, as General Counsel and Corporate Secretary. Prior to Visterra, Chris served in senior legal positions at Momenta Pharmaceuticals, Ironwood Pharmaceuticals and Genzyme Corporation.  Previously, he was a corporate,… READ MORE>>

As Chief Medical Officer, David Oldach oversees translational and early clinical drug development activities across a broad spectrum of diseases influenced by autoimmunity within the arenas of nephrology, rheumatology, transplant immunology and neurology. David Oldach joined Visterra in 2017 and has more than 25 years of experience in the biotechnology industry and academia. Prior to… READ MORE>>

As President and Chief Executive Officer, Brian Pereira oversees all aspects of Visterra and its interactions with the parent the company Otsuka, including research & development, accounting & finance, legal, pharmaceutical sciences & technology, operations, business development and strategy. Brian Pereira joined Visterra in 2013 and is a veteran biopharmaceutical and healthcare leader with experience… READ MORE>>

As Vice President, Translational Medicine, Asher Schachter is responsible for shepherding preclinical assets through clinical proof-of-concept. Asher joined Visterra in 2020. Prior to moving to industry, Asher practiced clinical pediatric nephrology at Boston Children’s Hospital. During his time there, he conducted translational research on focal segmental glomerulosclerosis (FSGS), and recurrence of FSGS after kidney transplantation…. READ MORE>>

As Chief Scientific Officer, Zachary Shriver is responsible for strategic thought leadership in the areas of Research and Pharmaceutical Sciences for the company. Zachary joined Visterra in 2009 as Vice President of Research and has over 20 years of experience in the biotechnology industry. Prior to Visterra, Zachary was one of the founding scientists at… READ MORE>>

As Vice President, Nonclinical Development, Susan Sloan is responsible for IND-enabling activities spanning preclinical, bioanalytical and pharmacology to transition programs from research to the clinic. Susan also currently oversees the Quality function. Susan joined Visterra in 2013 and has over 16 years of biologics drug development experience. Prior to joining Visterra, Susan worked at MassBiologics,… READ MORE>>